Dermatitis, Seborrheic: Clinical Trials

7 trials for Dermatitis, Seborrheic, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 recruiting, 1 unknown. 7 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 37Completed 5, Recruiting 1, Unknown 1
Phase 21Completed 1

Follow Dermatitis, Seborrheic: new trials by email Literature Review of Dermatitis, Seborrheic trials Research Report on Dermatitis, Seborrheic

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis
Roflumilast Foam 0.3%, Vehicle foam - Seborrheic Dermatitis
Phase 3RecruitingHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.3092026-11-122026-11-17
Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)
Roflumilast Foam, Vehicle Foam - Seborrheic Dermatitis
Phase 3CompletedArcutis Biotherapeutics, Inc.4572021-07-082024-03-12
Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis
Protopic (R), Mycoster (R) - Severe Seborrheic Dermatitis
Phase 3CompletedUniversity Hospital, Rouen1202014-01-012018-05-29
Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis
0.5% prednisolone acetate cream, 0.1% betamethasone valerate cream - Dermatitis, Atopic, Dermatitis, Contact
Phase 3UnknownMantecorp Industria Quimica e Farmaceutica Ltd.1702010-02-012009-11-11
K301 for the Treatment of Seborrhoeic Eczema (SE) of the Scalp
K301, Placebo - Seborrhoeic Eczema of the Scalp
Phase 3CompletedMoberg Pharma AB2012008-02-012010-06-04
Efficacy and Safety of ASF1057 in the Treatment of Seborrhoeic Dermatitis
ASF1057 - Seborrheic Dermatitis
Phase 3CompletedAstion Pharma A/S3002007-12-012008-06-03
Two Topical K40 Formulations in Adults With Seborrhoeic Dermatitis (SD) of the Scalp
K40a, K40b, Placebo - Seborrhoeic Dermatitis of the Scalp
Phase 2 / Phase 3CompletedMoberg Pharma AB982007-02-012010-06-04

Narrower conditions

Dandruff (1)  ·  Dermatitis, Atopic (1)  ·  Dermatitis, Contact (1)  ·  Psoriasis (1)

Broader conditions

Dermatitis (7)  ·  Sebaceous Gland Diseases (7)  ·  Skin Diseases (7)  ·  Skin Diseases, Eczematous (7)  ·  Skin Diseases, Papulosquamous (7)  ·  Skin and Connective Tissue Diseases (7)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Genetic Diseases, Inborn (1)  ·  Hypersensitivity (1)  ·  Hypersensitivity, Immediate (1)  ·  Immune System Diseases (1)  ·  Scalp Dermatoses (1)  ·  Skin Diseases, Genetic (1)

Interventions

Ciclopirox (1)  ·  Tacrolimus (1)

Sponsors

Moberg Pharma AB (2)  ·  Arcutis Biotherapeutics, Inc. (1)  ·  Astion Pharma A/S (1)  ·  Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (1)  ·  Mantecorp Industria Quimica e Farmaceutica Ltd. (1)  ·  University Hospital, Rouen (1)

Countries

Sweden (2)  ·  Canada (1)  ·  China (1)  ·  France (1)  ·  United States (1)

Top investigators

Adilson Costa, MD (1)  ·  David Berk, MD (1)  ·  Lennart Emtestam, MD (1)  ·  Peder M Andersen, MD (1)  ·  Roberta F. J. Criado, MD (1)